Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ciprostene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.42 |
| ▸ | PTGIR | P43119 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PTGFR | P43088 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprostene SCHEMBL4428358 | 1.00 | MEN1 (0.50) | MEN1KMT2APPARGPPARDPPARA | |
| Ciprostene SCHEMBL34269 | 0.91 | MEN1 (0.61) | MEN1KMT2APPARGPPARDPPARA | |
| Ciprostene SCHEMBL361116 | 0.90 | MEN1 (0.60) | MEN1KMT2APPARGPPARDPPARA | |
| SCHEMBL11891875 | 0.89 | MEN1 (0.47) | MEN1KMT2APPARGPPARDPPARA | |
| Epoprostenol SCHEMBL128619 | 0.74 | ALDH1A1 (0.82) | MEN1KMT2APPARGPPARDPPARA | |
| Epoprostenol SCHEMBL29121502 | 0.74 | ALDH1A1 (0.82) | MEN1KMT2APPARGPPARDPPARA | |
| Epoprostenol SCHEMBL4299219 | 0.74 | ALDH1A1 (0.82) | MEN1KMT2APPARGPPARDPPARA | |
| Epoprostenol SCHEMBL41344 | 0.74 | ALDH1A1 (0.82) | MEN1KMT2APPARGPPARDPPARA | |
| SCHEMBL29897015 | 0.72 | ALDH1A1 (0.53) | MEN1KMT2APPARGPPARDPPARA | |
| SCHEMBL7030341 | 0.72 | ALDH1A1 (0.53) | MEN1KMT2APPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109893528-A | Koumine treats the purposes of disorders of lipid metabolism and its related disease or illness | 福建医科大学 | 2019-06-18 | — | — | CN | claimed |
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | claimed |
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1785144-A2 | Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | Shering Corporation (US) | 2007-05-16 | — | — | EP | claimed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0257859-B1 | NOVEL COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-10-16 | — | — | EP | claimed |
| EP-0257859-A2 | Novel combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-03-02 | — | — | EP | claimed |
| WO-2020182077-A1 | USE OF GLI2 INHIBITOR AND METHOD FOR SCREENING COMPOUND INHIBITING GLI2 | 中国科学院动物研究所 | 2020-09-17 | — | — | WO | disclosed |
| CN-109893528-A | Koumine treats the purposes of disorders of lipid metabolism and its related disease or illness | 福建医科大学 | 2019-06-18 | — | — | CN | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-9096743-B2 | Process for forming films, fibers, and beads from chitinous biomass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2015-08-04 | — | — | US | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| WO-1999026620-A1 | CHOLINE ESTERS OF FATTY ACIDS AND THEIR USE IN THE TREATMENT OF STROKE | PROTARGA, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0257859-B1 | NOVEL COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-10-16 | — | — | EP | disclosed |
| US-4839169-A | BLOOD CLOT REMOVAL AND INHIBITION | BURROUGHS WELLCOME CO. (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0257859-A2 | Novel combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | MEN1 635/4885KMT2A 3795/4885PPARG 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.